A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis

In this phase 2 open-label randomized study, 31 patients with intermediate-2 or high-risk myelofibrosis received fedratinib 300, 400 or 500 mg once daily in consecutive 4-week cycles. Mean spleen volume reductions at 12 weeks (primary end point) were 30.3% (300 mg), 33.1% (400 mg) and 43.3% (500 mg)...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Blood Cancer J
Главные авторы: Pardanani, A, Tefferi, A, Jamieson, C, Gabrail, N Y, Lebedinsky, C, Gao, G, Liu, F, Xu, C, Cao, H, Talpaz, M
Формат: Artigo
Язык:Inglês
Опубликовано: Nature Publishing Group 2015
Предметы:
Original Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4558588/
https://ncbi.nlm.nih.gov/pubmed/26252788
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2015.63
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы